Skip to content

BioLux

Active Private limited companyfounded 2022active for 3 yearsPierre Schoonejansstraat 48, 1160 AuderghemKBO/BCE: BE 0794.448.707

Annual accounts 2025

micro format, filed on 19-06-2026, 42 days before the deadline
-€11,436
▼ €18,016
-€12,203
▼ €18,312
-€12,409
▼ €16,555
€3,049
▼ 80.3%
25.2%
▼ 33.8 percentage points
1.33
▼ 1.10

The micro format does not require turnover, and these accounts state none. Without turnover there is no EBIT margin either.

Balance sheet

balance sheet total €12,481 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

25.2%

Higher than 43% of the 25,388 companies filing micro accounts in retail trade (NACE 47) in 2025.

1.33

Higher than 46% of the 24,385 companies filing micro accounts in retail trade (NACE 47) in 2025.

-99.4%

Lower than 95% of the 24,575 companies filing micro accounts in retail trade (NACE 47) in 2025.

BioLux Middle half of the sector 80% of the sector Micro accounts in retail trade (NACE 47)

Net result: bottom quarter · Equity: middle half · Balance sheet total: bottom quarter · Working capital: middle half

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend20252024202313 months
--91
-12,8844,074-
3,04915,45811,312
25.2%58.9%56.6%
1.332.432.30
2.970.700.77
-395.2%26.7%64.9%
-99.4%15.7%36.8%

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend20252024202313 months
Balance sheet: assets
20/58 12,48126,38320,134
21/28 919191
28 919191
29/58 12,39026,29220,043
40/41 8,9549,9727,797
40 7,6475,5903,820
41 1,3074,3823,977
54/58 3,43616,32012,246
Balance sheet: equity and liabilities
10/49 12,48126,38320,134
10/15 3,14015,54911,402
10/11 4,0004,0004,000
13 -11,5497,402
133 -11,5497,402
14 -860--
17/49 9,34110,8348,731
42/48 9,34110,8348,731
44 7,2195,0882,414
440/4 7,2195,0882,414
45 2,1225,1135,669
450/3 2,1225,1133,169
454/9 --2,500
47/48 -632648
Income statement
9900 -11,4366,58012,356
640/8 7674721,676
9901 -12,2036,10810,680
75/76B 3250-
75 3250-
65/66B 5968108
65 5968108
9903 -12,2316,09010,572
67/77 1781,9443,169
9904 -12,4094,1467,402
9905 -12,4094,1467,402
Appropriation of the result
9906 -12,4094,1467,402
791/2 11,549--
691/2 -4,1467,402
6921 -4,1467,402
Document PDFPDFPDF

The full notes are in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 19-06-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 micro format 19-06-2026 2026-00176471 PDF
31-12-2024 micro format 23-06-2025 2025-00163601 PDF
31-12-2023 micro format 21-06-2024 2024-00147864 PDF

Investments

fixed assets acquired
Item202520242023
Financial fixed assets--€91

Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)

Insights on BioLux

The operating result for 2025 is a loss of €12,203, after a profit of €6,108 in 2024.

Debt's share of the balance-sheet total rises from 41.1% to 74.8%. Equity and debt are lower.

Next steps